The place of YKL-40 in non-small cell lung cancer

ONARAN, Hilal; TUTAR, Nuri; Gül, Şule; ÇETİNKAYA, Erdoğan; ZENGİ, Oğuzhan; GÜNEŞ KIRANKAYA, Ayşegül; ozgul, mehmet akif

The place of YKL-40 in non-small cell lung cancer

Ayşegül GÜNEŞ KIRANKAYA, (İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Biyokimya Bölümü, İstanbul, Türkiye)

Şule GÜL, (SB Yedikule Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Cerrahisi Kliniği, İstanbul, Türkiye)

Nuri TUTAR, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Kayseri, Türkiye)

Mehmet Akif ÖZGÜL, (SB Yedikule Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Cerrahisi Kliniği, İstanbul, Türkiye)

Erdoğan ÇETİNKAYA, (SB Yedikule Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Cerrahisi Kliniği, İstanbul, Türkiye)

Oğuzhan ZENGİ, (İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Biyokimya Bölümü, İstanbul, Türkiye)

Hilal ONARAN (Amasya Merzifon Kara Mustafa Paşa Devlet Hastanesi, Göğüs Hastalıkları Kliniği, Amasya, Türkiye)

Tüberküloz ve Toraks

1 0

Yıl: 2014 Cilt: 62 Sayı: 4 Sayfa Aralığı: 273 - 278 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The place of YKL-40 in non-small cell lung cancer

Öz:

Giriş : Primer akciğer kanserinin %80'ini olu şturan küçük hücreli dışı akciğer kanseri (KHDAK)nin sa ğkalım oran ı, tedaviye rağmen%15'ten az olup hala dü şük seyretmektedir. Kanserin biyolojik davran ışı tedaviye ba şlamadan önce belirlenebilirse, bu bilgiler tedaviyi yönlendirme, de ğerlendirme ve klinik çalışmaları planlamada kullan ılabilir. Serum YKL-40 seviyelerinin prognostik de ğerleri birçokkanser tiplerinde incelenmiş ve daha çok agresif klinik gidişi yansıttığı gözlenmiştir. Biz de KHDAKlı hastalarda serum YKL-40 seviye-lerinin kanser evresini belirlemedeki rolünü ara ştırdık.Materyal ve Metod: Yeni tan ı alm ış ve daha önce cerrahi, kemoterapi, radyoterapi, semptomatik tedavi almam ış 49 (%89.1)u erkekve 6 (%10.9)s ı kadın toplam 55 hastan ın venöz kan örneklerinde YKL-40 düzeylerine bak ıldı. Bilgisayarlı tomografi (BT), pozitronemisyon tomografi (PET), kraniyal manyetik rezonans görüntüleme (MRG), bronkoskopi, mediastinoskopi bulgularına dayan ılarakTNM evrelendirilmesi yapıldı. KHDAKlı hastalar erken evre ve ileri evre olarak iki gruba ayrılarak incelendi. Grup A: Evre Ia, Ib, IIa,IIb, Grup B: Evre IIIa, IIIb, IV.Bulgular: Evreler aç ısından erken evre (Grup A) ve ileri evre (Grup B)ye ayrılm ış olan hasta grubumuzda YKL-40 düzeylerini karşıla ştırdığım ızda aralarındaki fark istatistiksel olarak anlamlı bulundu (p< 0.05). YKL-40 düzeyleri ile ya ş aras ında orta derecede (r=0.48; p< 0.001) korelasyon saptandı.Sonuç: YKL-40 düzeylerini ileri evre KHDAK (Evre III-IV) grubunda erken evre (Evre I-II) hasta grubuna göre anlamlı olarak yüksekbulduk. YKL-40 düzeylerinin yüksek bulunmas ı durumunda hastalığın ileri evrede olabilece ği akla getirilmeli ve bu konuda ileri tetkikler yapılmalıdır.

Anahtar Kelime:

Konular: Solunum Sistemi Kulak, Burun, Boğaz

Küçük hücreli d ışı akciğ er kanserinde YKL-40 ın yeri

Öz:

Introduction: Despite varies treatment options, the survival rate of non-small cell lung cancer (NSCLC) is less than 1%. If biologicalbehaviour of any cancer could be known, the information would potentially tailor the clinical work-up, assesment and treatment.The prognostic value of serum YKL-40 level has been investigated in different types of cancer and showed poor prognostic indicationwith more aggressive clinical course. We studied the role of serum YKL-40 levels in patients with NSCLC to determine the stage.Materials and Methods: Serum YKL-40 levels in venous blood samples of 55 patients was studied. 49 (89.1%) male and 6 (10.9%)female newly diagnosed NSCLC patients whom received neither cancer specific or symptom relieving treatment are enrolled. TNMstaging was determined based on the findings of computerized tomography (CT), positron emission tomography (PET), cranial mag-netic resonance imaging (MRI), bronchoscopy and mediastinoscopy. The patients with NSCLC were divided into two groups; GroupA: stage Ia, Ib, IIa, IIb, Group B: stage IIIa, IIIb and IV.Results: There was a statistical difference in YKL-40 serum levels between groups (Group A, Group B) when compared (p< 0.05).A medium and statistical correlation was found (r= 0.48; p< 0.01)between YKL-40 levels and age.Conclusion: YKL-40 levels in advanced stage NSCLC (stage III, IV)was found to be significantly high compared to early stage. Itshould be kept in mind that when YKL levels are high, higherstages of the disease should be suspected and future tests shouldbe performed.

Anahtar Kelime:

Konular: Solunum Sistemi Kulak, Burun, Boğaz

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Krainhöfer J, Walther M, Steinert M, Reissig A. Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice. Biomed Res Int 2014;2014:987150.
2. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a Biologic marker of non- small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163-9.
3. León-Atance P, Moreno-Mata N, González-Aragoneses F, Cañizares-Carretero MÁ, García-Jiménez MD, Genovés- Crespo M, et al. Multicenter analysis of survival and prog- nostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. Arch Bronconeumol 2011;47(9):441-6.
4. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentra- tion of YKL-40- an independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer. Cancer 2010;116(17):4114-121.
5 Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
6. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces prolif- erative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondro- cytes. Biochem Biophys Res Commun 2001;285:926-31.
7. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-a. Biochem J 2004;380:651-9.
8. Johansen JS, Cintin C, Jørgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995;31A:1437-42.
9. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
10. Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003;80(1):15-21.
11. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, et al. Early detection and prognosis of ovari- an cancer using serum YKL-40. J Clin Oncol 2004;22(16):3330-9.
12. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with meta- static melanoma. Cancer 2006;106:1130-9.
13. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66(5):503-13.
14. Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F, et al. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol 2008;26(1):47-52.
15. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, et al. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25(8):801-9.
16. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15(2):194-202.
17. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colo- rectal carcinoma is related to short survival. Cancer 2002;95:267-74.
18. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/ neu and YKL-40 independently reflect aggressive- ness of metastatic breast cancer. Clin Cancer Res 2003;9:501-12.
19. Høgdall EVS, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncology Reports 2003;10:1535-8.
20. Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48(2):223- 31.
21. Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int 2011;10(6):605-10.
22. Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non- small cell lung cancer. Acta Oncol 2010;49(6):861-4.
23. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage group- ings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
24. Xu CH, Yu LK, Hao KK. Serum YKL-40 Level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9(5):e96384.

APA	GÜNEŞ KIRANKAYA A, Gül Ş, TUTAR N, ozgul m, ÇETİNKAYA E, ZENGİ O, ONARAN H (2014). The place of YKL-40 in non-small cell lung cancer. , 273 - 278.
Chicago	GÜNEŞ KIRANKAYA Ayşegül,Gül Şule,TUTAR Nuri,ozgul mehmet akif,ÇETİNKAYA Erdoğan,ZENGİ Oğuzhan,ONARAN Hilal The place of YKL-40 in non-small cell lung cancer. (2014): 273 - 278.
MLA	GÜNEŞ KIRANKAYA Ayşegül,Gül Şule,TUTAR Nuri,ozgul mehmet akif,ÇETİNKAYA Erdoğan,ZENGİ Oğuzhan,ONARAN Hilal The place of YKL-40 in non-small cell lung cancer. , 2014, ss.273 - 278.
AMA	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H The place of YKL-40 in non-small cell lung cancer. . 2014; 273 - 278.
Vancouver	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H The place of YKL-40 in non-small cell lung cancer. . 2014; 273 - 278.
IEEE	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H "The place of YKL-40 in non-small cell lung cancer." , ss.273 - 278, 2014.
ISNAD	GÜNEŞ KIRANKAYA, Ayşegül vd. "The place of YKL-40 in non-small cell lung cancer". (2014), 273-278.

APA	GÜNEŞ KIRANKAYA A, Gül Ş, TUTAR N, ozgul m, ÇETİNKAYA E, ZENGİ O, ONARAN H (2014). The place of YKL-40 in non-small cell lung cancer. Tüberküloz ve Toraks, 62(4), 273 - 278.
Chicago	GÜNEŞ KIRANKAYA Ayşegül,Gül Şule,TUTAR Nuri,ozgul mehmet akif,ÇETİNKAYA Erdoğan,ZENGİ Oğuzhan,ONARAN Hilal The place of YKL-40 in non-small cell lung cancer. Tüberküloz ve Toraks 62, no.4 (2014): 273 - 278.
MLA	GÜNEŞ KIRANKAYA Ayşegül,Gül Şule,TUTAR Nuri,ozgul mehmet akif,ÇETİNKAYA Erdoğan,ZENGİ Oğuzhan,ONARAN Hilal The place of YKL-40 in non-small cell lung cancer. Tüberküloz ve Toraks, vol.62, no.4, 2014, ss.273 - 278.
AMA	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H The place of YKL-40 in non-small cell lung cancer. Tüberküloz ve Toraks. 2014; 62(4): 273 - 278.
Vancouver	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H The place of YKL-40 in non-small cell lung cancer. Tüberküloz ve Toraks. 2014; 62(4): 273 - 278.
IEEE	GÜNEŞ KIRANKAYA A,Gül Ş,TUTAR N,ozgul m,ÇETİNKAYA E,ZENGİ O,ONARAN H "The place of YKL-40 in non-small cell lung cancer." Tüberküloz ve Toraks, 62, ss.273 - 278, 2014.
ISNAD	GÜNEŞ KIRANKAYA, Ayşegül vd. "The place of YKL-40 in non-small cell lung cancer". Tüberküloz ve Toraks 62/4 (2014), 273-278.